Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the efficacy and safety of using afatinib (BIBW 2992)
to treat non-small cell lung cancer patients considered unfit for chemotherapy and have
either suspected or confirmed Epidermal Growth Factor Receptor (EGFR) mutation.